Tigilanol tiglate is an oncolytic small molecule that induces immunogenic cell death and enhances the response of both target and non-injected tumors to immune checkpoint blockade

Tigilanol tiglate is an oncolytic small molecule that induces immunogenic cell death and enhances the response of both target and non-injected tumors to immune checkpoint blockade

Background Tigilanol tiglate (TT) is a protein kinase C (PKC)/C1 domain activator currently being developed as an intralesional agent for the treatment of various (sub)cutaneous malignancies. Previous work has shown that intratumoral (I.T.) injection of TT causes vascular disruption with concomitant...

詳細記述

書誌詳細
主要な著者: Kevin Hendrawan, Kelly M Brooks, Pei-Yi Yap, Blake Ferguson, Motoko Koyama, Herlina Handoko, Jenny Johns, Natasa Broit, Praphaporn Stewart, Daniel Shelley, Tracey McMahon, Yi Chieh Lim, Giovanni Appendino, Jason K Cullen, Zara C Bruce, Steven M Ogbourne, Paul W Reddell, Glen M Boyle, Peter G Parsons, Jacinta L Simmons, Emily S Wilson, Marjorie M A de Souza, Tam Hong Nguyen, Alberto Pagani, Victoria A Gordon
フォーマット: 論文
言語:English
出版事項: BMJ Publishing Group 2024-04-01
シリーズ:Journal for ImmunoTherapy of Cancer
オンライン･アクセス:https://jitc.bmj.com/content/12/4/e006602.full

インターネット

https://jitc.bmj.com/content/12/4/e006602.full

類似資料